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Introduction
Coronary artery disease is one of the most 
common dysfunctions of the cardiovascular system 
[1]. Anticoagulant therapy is particularly important 
in the periprocedural period in the case of invasive 
treatment of acute coronary syndrome (ACS). 
Since the last consensus statement of the Polish 
expert group for Association on Cardiovascular In-
terventions of the Polish Cardiac Society published 
in 2014 [2], new circumstances have occurred that 
triggered the group to revise the viewpoint: 1) the 
new European Society of Cardiology guidelines on 
myocardial revascularization announced in 2018 
provided indications for the use of bivalirudin in 
ACS; 2) new studies were published that provided 
essential new clinical evidence [3–6]; and 3) up-
dated bivalirudin reimbursement code now allows 
for its unlimited use in myocardial infarction (MI) 
patients in Poland [7]. This is a 5-year update of 
the recommendations on the use of bivalirudin 
for percutaneous coronary intervention (PCI) of 
in ACS, tailored to the Polish healthcare setting. 
Thrombus formation in ACS  
and after PCI
Percutaneous coronary intervention aims to 
restore the flow through the coronary artery in the 
setting of ACS. However, it is also associated with 
an increased risk of stent thrombosis. The inci-
dence of thrombosis in contemporary drug-eluting 
stent is approximately 0.7% over 1 year [8]. The 
risk is higher in the case of stent implantation in 
the setting of ACS as compared to the elective an-
gioplasty, which is affected by disturbed properties 
of the coagulation system and a reduced response 
to pharmacotherapy. Nevertheless, proper phar-
macotherapy with antiplatelet and anticoagulant 
agents may reduce this risk.
The mechanism of action of bivalirudin 
vs. unfractionated heparin
Bivalirudin is a synthetic polypeptide consist-
ing of 20 amino acids. Unlike unfractionated heparin 
(UFH), the mechanism of its action is independent 
of antithrombin, so is classified as direct thrombin 
inhibitors. This effect applies to the fluid phase and 
clot-bound of thrombin. Compared to UFH, which 
inhibits just about 50% of thrombin activity, biva-
lirudin suppresses it entirely allowing for effective 
and predictable anticoagulation effect. The inhibi-
tion of thrombin takes place in two mechanisms. 
One of them is the inhibition of the active catalytic 
site of thrombin, and the second is the impact on 
the fibrin binding site (exosite 1). This means bi-
valirudin is able to inhibit active thrombin as well 
as thrombin bounded to platelets in a thrombus. 
In addition, platelet activation typical for UFH 
is not observed after bivalirudin, which reduces 
thrombin-dependent platelet aggregation by affect-
ing the protease-activated receptor [9]. In contrary 
to UFH, bivalirudin, a direct thrombin inhibitor, 
is not dependent on the levels of antithrombin 3. 
After intravenous administration, the onset of 
bivalirudin action is rapid, reaching a maximum 
serum concentration after 15–20 minutes. The 
half-life time of bivalirudin is approximately 
25 minutes, which is more than two times shorter than 
an hour of UFH [10]. Bivalirudin is administered 
as an intravenous bolus of 0.75 mg/kg. It is then 
followed by an infusion of 1.75 mg/kg throughout 
the time of the procedure that should be continued 
up to 4 hours after PCI. Such a pharmacological 
profile is particularly beneficial in case of peripro-
cedural administration of anticoagulants. As in the 
case of UFH, the anticoagulant effect of bivalirudin 
can be assessed on-site by active clothing time and 
in laboratory by activated partial thromboplastin 
time [11]. In case of overt bleeding, the following 
methods are recommended to restore proper blood 
coagulation in bivalirudin recipients: ultrafiltration 
and hemodialysis, administration of recombinant fac-
tor VIIa, cryoprecipitate or fresh frozen plasma [12].
Bivalirudin in the revascularization  
of the myocardium in ACS
The 2018 European Society of Cardiology 
guidelines on the myocardial revascularization 
indicate that anticoagulation should be selected 
according to both ischemic and bleeding risks, 
and according to the efficacy–safety profile of the 
chosen agent. Although, routine use of UFH is 
indicated (class of recommendations I; level of 
evidence B), the routine use of bivalirudin as an 
alternative to UFH may be considered in patients 
with ST-segment elevation myocardial infarction 
(STEMI) (class of recommendations IIb; level of 
evidence A) and in selected patients with non-ST-
-segment elevation acute coronary syndrome (class 
of recommendations IIb; level of evidence A) [7].
Since the publication of the above guidelines, 
essential trials comparing the efficacy and safety 
of bivalirudin in comparison with UFH have been 
published. One-year results of the Minimizing 
Adverse Hemorrhagic Events by Transradial 
2 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 1
Access Site and Systemic Implementation of 
Angiox (MATRIX) randomized trial showed in 
a group of 7213 patients comparable rate of major 
adverse cardiac event (MACE)/net adverse clinical 
events between bivalirudin and UFH in the setting 
of STEMI and non-ST-segment myocardial infarc-
tion (NSTEMI). However, secondary endpoint 
analysis revealed in patient treated with bivalirudin 
comparted to UFH arm a significant decrease in 
all bleedings (13.6% vs. 15.9%, p < 0.05), ma-
jor bleedings, i.e. Bleeding Academic Research 
Consortium (BARC) type 3 and 5 (2.2% vs. 3.3%, 
p < 0.001), all-cause mortality (3.6% vs. 4.6%, 
p < 0.05) and cardiovascular death (2.2% vs. 3.0%, 
p < 0.05) [3]. On the other hand, there was a nu-
merically higher rate of definite or probable stent 
thrombosis (1.4% vs. 1.2%) in bivalirudin group 
during the follow-up. Half of patients in MATRIX 
trial were pre-treated with P2Y12 inhibitors be-
fore catheterization procedure and ticagrelor or 
prasugrel were used in 1/3 of patients [13]. Of note, 
a lack of prolonged bivalirudin infusion after PCI 
did not increase this risk of stent thrombosis, re-
peat revascularization or MACE. In contrary, the 
VALIDATE-SWEDEHEART randomized trial, 
which was taken into consideration in the myocar-
dial revascularization guidelines, showed in a group 
of 6006 STEMI and NSTEMI patients a numerically 
lower rate of definite stent thrombosis in the biva-
lirudin group as compared to UFH (0.4% vs. 0.7%, 
p = 0.09) [14]. It should be underlined that nearly 
all patients (97%) received potent P2Y12 inhibitors 
(ticagrelor or prasugrel). Although, the composite 
primary end-point consisting of all-cause mortality, 
MI or major bleeding, did not differ between the 
two arms, there was a trend of benefit in the biva-
lirudin treated female patients (13.6% vs. 17.1%, 
p = 0.05) over a period of 180 days. The risk of 
major bleeding in both arms was the same (8.6%). 
The latest meta-analysis published in 2018 by 
Anantha-Narayanan that included 22 randomized 
studies and four subgroup analysis with 53,364 
patients compared the use of the bivalirudin to 
heparin, with and without adjunctive glycoprotein 
IIb/IIIa inhibitors (GPI) in PCI [5]. Over a mean 
follow-up of 192 ± 303 days, the major bleeding 
was lower in the bivalirudin group with (risk ratio 
[RR] 0.64, 95% confidence interval [CI] 0.53–0.77, 
p < 0.001) and without (RR 0.71, 95% CI 0.51–0.99, 
p = 0.041) provisional or routine use of GPIs. 
There was no difference in all-cause mortality (RR 
0.93; 95% CI 0.82–1.05, p = 0.260), target vessel 
revascularization (RR 1.17; 95% CI 0.93–1.46, 
p = 0.174) or stroke (RR 0.91; 95% CI 0.71–1.18, 
p = 0.490), despite a higher risk of stent thrombo-
sis in bivalirudin group (RR 1.32; 95% CI 1.04–1.68, 
p = 0.022).
In pre-treated patients, who received UFH 
before cathlab admission (ambulance/emergency 
department), the use of bivalirudin is feasible and 
had been correlated with lower risk of all-cause 
mortality and MACE comparted to the continua-
tion of UFH [4].
Bivalirudin as an anticoagulant therapy 
in high bleeding risk patients
Bivalirudin is recommended and should be 
used as an alternative to UFH in patients with 
heparin-induced thrombocytopenia (class of recom-
mendations I; level of evidence C) [7]. 
The use of non-vitamin K antagonist oral an-
ticoagulants (NOACs) in primary and secondary 
prevention of stroke among Polish patients with 
atrial fibrillation presenting with ACS is rapidly 
increasing.
Considering the ORBITA trial results, we 
should also expect a growing number of patients 
with complex coronary artery disease and/or 
peripheral artery disease treated with low-dose 
rivaroxaban (2.5 mg b.d.) on top of acetylsalicylic 
acid, coming to the cathlab for subsequent inter-
ventional procedures due to ACS [15]. Importantly, 
their use is associated with an increase of major 
bleeding events during urgent PCI. In the clinical 
practice, there is very limited possibility to as-
sess the anticoagulation activity of dabigatran and 
xabans, especially in a timely manner required in 
the acute setting of ACS. Patients on NOACs were 
excluded from most of the trials, tough given the 
consistently low rates of bleeding with bivalirudin 
compared to heparin, it may be prudent to use bi-
valirudin in patients who have taken the last dose 
of NOAC within 4 hours. Measures to reduce this 
risk over the acute, periprocedural period include 
use of radial access, refrain from GPI and use of 
bivalirudin instead of UFH [16]. Furthermore, 
high bleeding risk has been identified in patients 
> 75 years of age, female, obese (body mass index 
[BMI] > 30 kg/m2) and chronic kidney disease. 
Similarly, patients with peripheral artery disease 
are considered as a high-risk group for hemor-
rhagic events. Safety of bivalirudin was tested in 
the group of patients undergoing percutaneous 
peripheral interventions. The total number of 
hemorrhagic complications was lower, especially 
hematomas at the puncture site in comparison to 
patients receiving UFH [17]. Therefore, use of 
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bivalirudin should be considered in all patients with 
increased risk of bleeding, who undergo PCI for 
ACS regardless of the type of vascular access and 
use of GPI (Table 1, Fig. 1). To reduce this risk of 
acute and long-term stent thrombosis a potent an-
tiplatelet treatment with either ticagrelor or prasu-
grel could be considered in patients not requiring 
oral anticoagulation. As the potent P2Y12 inhibitors 
were not available at the time when the summary 
of product characteristic (SPC) for bivalirudin was 
developed (20.09.2004), this combination was not 
included in the drug documentation. 
Bivalirudin and glycoprotein  
IIb/IIIa inhibitors
In patients treated with bivalirudin the use 
of GPI (eptifibatide, abciximab, tirofiban) is safe 
and may be considered as bailout in selected clinical 
scenarios, i.e. thrombus visible in coronary angio-
graphy, acute stent thrombosis [18–20]. Although, 
in clinical practice the use of GPI in bivalirudin-
treated patients will be less common that in those 
on UFH.
Periprocedural vs. prolonged infusion  
of bivalirudin
Conflicting data exist as far as prolonged bivali-
rudin infusion is concerned in ACS [3, 21]. Most evi-
dence for the bivalirudin use came from clinical trials 
in which patients were treated with less potent oral 
P2Y12 inhibitors (clopidogrel). At that time prolonged 
infusion up to 4 hours after PCI seemed to be rational 
especially in STEMI and has been included in the 
SPC developed several years ago (20.09.2004). Acute 
stent thrombosis is a modifiable phenomenon and is 
reduced mainly by use of potent P2Y12 inhibitors (tica-
grelor, prasugrel) [22, 23]. Therefore, in respect to 
the published data and clinical experience, in patients 
pre-treated with ticagrelor or prasugrel, in whom the 
PCI result is optimal, the periprocedural bivalirudin 
infusion should be continued after the procedure to 
empty the first vial of the drug only.
Bivalirudin as an anticoagulant therapy 
in special situations
A similar safety and efficacy profile of biva-
lirudin and UFH has also been demonstrated in 
cardiac surgery patients. The use of bivalirudin 
should be considered as an alternative for patients 
treated with extracorporeal membrane oxygena-
tion (ECMO) or ventricular assist devices, re-
quiring long-term treatment with heparin, which 
significantly increases the risk of heparin-induced 
thrombocytopenia [24]. 
Cost–effectiveness of bivalirudin  
and reimbursement indications
Historically bivalirudin vs. heparin has been 
shown as a cost–effective option in multiple coun-
tries [25, 26]. In Poland, despite higher per patient 
costs associated with the administration of bivaliru-
din (1,750 PLN) than UFH (100 PLN), the Agency 
for Health Technology Assessment and Tariff Sys-
tem (AOTMiT) confirmed that use of bivalirudin is 
cost–effective also in the Polish healthcare system. 
Bivalirudin is reimbursed by the National Health 
Fund and a higher initial cost is offset by the reduc-
tion in bleeding events, transfusion, urgent surgi-
cal procedures and length of hospital stay, which 
increase the cost of hospitalization by nearly 40%. 
As by the Polish reimbursement catalogue, bi-
valirudin is currently indicated in patients with MI 
(STEMI or NSTEMI) to optimize PCI outcomes. 
This reimbursement code (5.53.01.0001469) is 
Table 1. Procedural and clinical factors in favor 
of the use of bivalirudin instead of unfraction-
ated heparin during percutaneous coronary  
intervention in acute coronary syndrome.
Procedural and pharmacological factors
Femoral access
Chronic use of NOAC/VKA (uninterrupted)
Pre-treatment with oral potent P2Y12 inhibitor  
(ticagrelor, prasugrel)
Patient-related factors
Age > 75 years
Female gender
BMI < 20 or BMI > 30 kg/m2
Previous gastrointestinal bleeding
Previous hemorrhagic stroke
Chronic kidney disease (eGFR 30–60 ml/min/1.73 m2)
Frailty
Increased bleeding risk related to other factors
Anticoagulant of choice
Heparin-induced thrombocytopenia 
BMI — body mass index; eGFR — estimated glomerular filtration 
rate; NOAC — non-vitamin K antagonist oral anticoagulants;  
VKA — vitamin K antagonists
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unlimited and is not subtracted from the annual 
contract budget. This code can be claimed when 
added up to the primary PCI procedure, in specific 
the two-stage PCI for ACS > 3 days (E11), PCI for 
ACS (E12G) and PCI for ACS with complications 
> 7 days (E15). We recommend that bivalirudin is 
used in all MI patients with high bleeding risk (as 
defined in Table 1 and Fig. 1). Thus, in the remain-
ing patients, characterized by a low bleeding and 
high ischemic risk, a GPI should be considered. 
We urge that a detailed analysis is required to 
establish an incremental cost–effectiveness ratio 
from the healthcare service provider perspective 
in the real-world setting. 
Summary
Recently published studies and the meta-
analyses allow to better define the indications 
for bivalirudin in ACS patients undergoing PCI. 
Bivalirudin in contrast to UFH is characterized 
by more predictable anticoagulation effect and 
shorter half-life time. It has been showed that 
administration of bivalirudin in the periprocedural 
phase was associated with lower risk of all bleed-
ing and major bleeding events that may translate 
to lower all-cause mortality and cardiovascular 
death. Therefore, the use of bivalirudin should be 
considered in all ACS patients with high bleeding 
Figure 1. Procedural and clinical factors in favor of the use of bivalirudin instead of unfractionated heparin during 
percutaneous coronary intervention in acute coronary syndrome; BMI — body mass index; HIT — heparin-induced 
thrombocytopenia; NOAC — non-vitamin K antagonist oral anticoagulants; VKA — vitamin K antagonists.
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risk, including patients on NOAC, female, elderly, 
obese and with chronic kidney disease. It is im-
portant to ensure regular review of new evidence 
to identify future subgroups of patients that may 
benefit most from bivalirudin as compared to stand-
ard UFH treatment.
KEY MESSAGES
The use of bivalirudin may be considered as an  
alternative to UFH in selected ACS patients to  
optimize PCI outcomes
Specific benefits can be expected in high bleeding 
risk patients, especially: 
•	Procedural and pharmacological factors: femoral 
access, chronic use of NOAC/vitamin K antagonists, 
pre-treatment with oral potent P2Y12 inhibitor
•	Patient-related factors: age > 75 years, female 
gender, BMI < 20 or BMI > 30 kg/m2, previous 
gastrointestinal bleeding, previous hemorrhagic 
stroke, chronic kidney disease (estimated glomerular 
filtration rate 30–60 mL/min/1.73 m2), frailty,  
increased bleeding risk related to other factors
•	Anticoagulant of choice: heparin-induced  
thrombocytopenia
The recently updated reimbursement bivalirudin 
code allows for its unlimited use in MI patients  
undergoing PCI in Poland
Conflict of interest: Łukasz Kołtowski — 
Accord, AstraZeneca, Boehringer Ingelheim, 
Polpharma; Jacek Legutko — AstraZeneca, Bayer, 
MSD; Krzysztof J. Filipiak — AstraZeneca, Bayer, 
Boehringer Ingelheim, MSD, Pfizer, Polpharma, 
Sanofi Aventis; Artur Dziewierz — none declared; 
Stanisław Bartuś — none declared; Paweł Buszman 
— none declared; Piotr Buszman — none 
declared; Dariusz Ciećwierz — none declared; 
Maciej Dąbrowski — none declared; Sławomir 
Dobrzycki — AstraZeneca, Bayer, Boehringer 
Ingelheim, MSD, Pfizer, Polpharma, Sanofi Aventis; 
Robert Gil — Bayer; Jarosław Gorący — none 
declared; Marek Grygier — none declared; Miłosz 
Jaguszewski — Boheringer Ingelheim, Abbott, 
Servier, AstraZeneca, Pfizer; Janusz Kochman — 
none declared; Jacek Kubica — AstraZeneca, Bayer, 
Boehringer Ingelheim, Pfizer, Sanofi Aventis; 
Wiktor Kuliczkowki — AstraZeneca, Bayer, 
Boehringer Ingelheim, Boston Scientific; Piotr 
Lodziński — none declared; Andrzej Ochała — 
none declared; Krzysztof Reczuch — none declared; 
Adam Witkowski — none declared; Wojciech 
Wojakowaki — none declared; Jarosław Wójcik — 
none declared; Dariusz Dudek — Accord.
References
1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiol-
ogy of coronary heart disease and acute coronary syndrome. 
Ann Transl Med. 2016; 4(13): 256, doi: 10.21037/atm.2016.06.33, 
indexed in Pubmed: 27500157.
2. Wożakowska-Kapłon B, Lesiak M, Ochała A, et al. [Bivalirudine 
use in the acute myocardial infarction in patients undergoing per-
cutaneous coronary interventions: consensus statement of ex-
perts from the Cardiovascular Pharmacotherapy Working Group 
and the Association on Cardiovascular Interventions of the Polish 
Cardiac Society]. Kardiol Pol. 2014; 72(8): 761–765, doi: 10.5603/
KP.2014.0159, indexed in Pubmed: 25155855.
3. Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral 
access and bivalirudin versus unfractionated heparin in invasive-
ly managed patients with acute coronary syndrome (MATRIX): 
final 1-year results of a multicentre, randomised controlled 
trial. Lancet. 2018; 392(10150): 835–848, doi: 10.1016/S0140-
6736(18)31714-8, indexed in Pubmed: 30153988.
4. Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switch-
ing from unfractionated heparin to bivalirudin during primary 
percutaneous coronary intervention. Catheter Cardiovasc In-
terv. 2019; 93(2): 241–247, doi:  10.1002/ccd.27828, indexed in 
Pubmed: 30269393.
5. Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin 
versus heparin in percutaneous coronary intervention: A sys-
tematic review and meta-analysis of randomized trials stratified 
by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 
10(6): 3341–3360, doi: 10.21037/jtd.2018.05.76, indexed in Pub-
med: 30069330.
6. Grajek S, Michalak M, Gwizdała A, et al. Patients treated with 
bivalirudin are still at higher risk of stent thrombosis: a compre-
hensive meta-analysis of randomised clinical trials of bivalirudin 
and heparin for percutaneous coronary interventions. Kardiol 
Pol. 2018; 76(4): 740–749, doi: 10.5603/KP.a2018.0024, indexed 
in Pubmed: 29350380.
7. Neumann F-J, Ahlsson A, Alfonso F, et al. 2018 ESC/EACTS 
Guidelines on myocardial revascularization. Eur Heart J. 2018; 
34(10): 2949.
8. Kereiakes D, Yeh R, Massaro J, et al. Stent thrombosis in drug-
eluting or bare-metal stents in patients receiving dual antiplate-
let  therapy. JACC: Cardiovasc Interv. 2015; 8(12): 1552–1562, 
doi: 10.1016/j.jcin.2015.05.026.
9. Kam PCA, Kaur N, Thong CL. Direct thrombin inhibitors: 
pharmacology and clinical relevance. Anaesthesia. 2005; 60(6): 
565–574, doi: 10.1111/j.1365-2044.2005.04192.x, indexed in Pub-
med: 15918828.
10. Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: 
A Review of the Pharmacology, Dosing, and Complications. Curr 
Emerg Hosp Med Rep. 2013; 1(2): 83–97, doi: 10.1007/s40138-
013-0014-6, indexed in Pubmed: 23687625.
11. Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant 
effects of hirulog, a novel thrombin inhibitor, in patients with 
coronary artery disease. Am J Cardiol. 1993; 71(10): 778–782, 
indexed in Pubmed: 8456753.
12. Stratmann G, deSilva A, Tseng E, et al. Reversal of direct throm-
bin inhibition after cardiopulmonary bypass in a patient with hep-
arin-induced thrombocytopenia. Anesth Analg. 2004: 1635–1639, 
doi: 10.1213/01.ane.0000114072.71353.d5.
6 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 1
13. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfrac-
tionated Heparin in Acute Coronary Syndromes. N Engl J Med. 
2015; 373(11): 997–1009, doi: 10.1056/nejmoa1507854.
14. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus 
Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 
2017; 377(12): 1132–1142, doi: 10.1056/nejmoa1706443.
15. Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antag-
onist oral anticoagulants (NOACs) in the treatment of coronary 
and peripheral atherosclerosis. Expert Consensus. Kardiol Pol. 
2019 [Epub ahead of print], doi: 10.5603/KP.a2019.0033, indexed 
in Pubmed: 30799544.
16. Mallifi JR, Lotfi AS. Management of STEMI in Patients on 
NOACs and Undergoing Primary PCI. Expert Analysis ACC web-
site 2015. https://www.acc.org/latest-in-cardiology/articles/2015/ 
/10/22/10/43/management-of-stemi-in-patients-on-noacs-and-
undergoing-primary-pci.
17. Wojtasik-Bakalarz J, Kleczyński P, Zasada W, et al. Safety of 
bivalirudin versus unfractionated heparin in endovascular re-
vascularization of peripheral arteries in short- and long-term 
follow-up. Advances in Inverventional Cardiology. , doi: 10.5114/ 
/aic.2019.81757.
18. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary 
abciximab and aspiration thrombectomy in patients with large an-
terior myocardial infarction: the INFUSE-AMI randomized trial. 
JAMA. 2012; 307(17): 1817–1826, doi:  10.1001/jama.2012.421, 
indexed in Pubmed: 22447888.
19. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin dur-
ing primary PCI in acute myocardial infarction. N Engl J Med. 
2008; 358(21): 2218–2230, doi:  10.1056/NEJMoa0708191, in-
dexed in Pubmed: 18499566.
20. Stone G, McLaurin B, Cox D, et al. Bivalirudin for patients 
with acute coronary syndromes. N Engl J Med. 2006; 355(21): 
2203–2216, doi: 10.1056/nejmoa062437.
21. Steg PG, van ‘t Hof A, Hamm CW, et al. Bivalirudin started dur-
ing emergency transport for primary PCI. N Engl J Med. 2013; 
369(23): 2207–2217, doi: 10.1056/NEJMoa1311096, indexed in 
Pubmed: 24171490.
22. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopi-
dogrel in patients with acute coronary syndromes. N Engl J Med. 
2009; 361(11): 1045–1057.
23. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus 
Clopidogrel in Patients with Acute Coronary Syndromes. 
N Engl J Med. 2007; 357(20): 2001–2015, doi: 10.1056/nejmoa07 
06482.
24. Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for 
perioperative anticoagulation in cardiac surgery. Anesthesiology. 
2018; 128(2): 390–400, doi:  10.1097/ALN.0000000000001976, 
indexed in Pubmed: 29206646.
25. Schwenkglenks M, Brazier JE, Szucs TD, et al. Cost-effective-
ness of bivalirudin versus heparin plus glycoprotein IIb/IIIa in-
hibitor in the treatment of non-ST-segment elevation acute coro-
nary syndromes. Value Health. 2011; 14(1): 24–33, doi: 10.1016/j.
jval.2010.10.025, indexed in Pubmed: 21211483.
26. Borg S, Persson U, Allikmets K, et al. Comparative cost-ef-
fectiveness of anticoagulation with bivalirudin or heparin 
with and without a glycoprotein IIb/IIIa-receptor inhibitor in 
patients undergoing percutaneous coronary intervention in 
Sweden: a decision-analytic model. Clin Ther. 2006; 28(11): 
1947–1959, doi:  10.1016/j.clinthera.2006.11.013, indexed in 
Pubmed: 17213015.
www.cardiologyjournal.org 7
Łukasz Kołtowski et al., Bivalirudin use in ACS patients undergoing PCI in Poland
